Opportunities to exploit non-neutralizing HIV-specific antibody activity

Current HIV Research

Volumn 11, Issue 5, 2013, Pages 365-377

  Ackerman, Margaret E ^a   Alter, Galit ^b  

^a DARTMOUTH COLLEGE   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

ADCC; Antibody; Effector function; FcgR; HIV; IgG; Passive transfer; Phagocytosis; Vaccine

Indexed keywords

CD16 ANTIGEN; COMPLEMENT COMPONENT C1Q; FC RECEPTOR; FC RECEPTOR IIA; FC RECEPTOR IIB; FC RECEPTOR N; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN SUBCLASS; MANNOSE BINDING LECTIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B12; NON NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY STRUCTURE; ARTICLE; B LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); DENDRITIC CELL; EFFECTOR CELL; GENE REARRANGEMENT; GLYCOSYLATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; INFECTION SENSITIVITY; INNATE IMMUNITY; MACROPHAGE; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN POLYMORPHISM; VACCINATION;

AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; IMMUNITY, INNATE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN FC FRAGMENTS; RECEPTORS, IGG;

EID: 84889045001     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X113116660058     Document Type: Article

References (157)

1. Ackerman ME, Dugast AS, Alter G. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu Rev Med 2012; 63: 113-30.
2. Hessell AJ, Hangartner L, Hunter M, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 2007; 449(7158): 101-4.
3. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002; 18(16): 1197-205.
4. Hidajat R, Xiao P, Zhou Q, et al. Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 2009; 83(2): 791-801.
5. Florese RH, Demberg T, Xiao P, et al. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J Immunol 2009; 182(6): 3718-27.
6. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89. 6P challenge in rhesus macaques. J Virol 2010; 84(14): 7161-73.
7. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174(4): 2185-9.
8. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. AIDS Res Hum Retroviruses 2002; 18(16): 1197-205.
9. Alpert MD, Harvey JD, Lauer WA, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathog 2012; 8(8): e1002890.
10. Tyler DS, Lyerly HK, Weinhold KJ. Anti-HIV-1 ADCC. AIDS Res Hum Retroviruses 1989; 5(6): 557-63.
11. Sawyer LA, Katzenstein DA, Hendry RM, et al. Possible beneficial effects of neutralizing antibodies and antibody-dependent, cellmediated cytotoxicity in human immunodeficiency virus infection. AIDS Res Hum Retroviruses 1990; 6(3): 341-56.
12. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 2009; 23(8): 897-906.
13. Forthal DN, Landucci G, Daar ES. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol 2001; 75(15): 6953-61.
14. Tyler DS, Stanley SD, Nastala CA, et al. Alterations in antibodydependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990; 144(9): 3375-84.
15. Forthal DN, Landucci G, Keenan B. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses 2001; 17(6): 553-61.
16. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157(5): 2168-73.
17. Ahmad R, Sindhu ST, Toma E, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 2001; 21(3): 227-33.
18. Forthal DN, Landucci G, Haubrich R, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 1999; 180(4): 1338-41.
19. Forthal DN, Gilbert PB, Landucci G, Phan T. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol 2007; 178(10): 6596-603.
20. Bonsignori M, Pollara J, Moody MA, et al. Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 2012; 86(21): 11521-32.
21. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366(14): 1275-86.
22. Janeway CA, Walport M, Schlomchik MJ. Immunobiology, the immune system in health and disease. 6th Edition ed. Lawrence E, editor. New York, NY: Garland Science Publishing; 2005.
23. Burton DR, Dwek RA. Immunology. Sugar determines antibody activity. Science 2006; 313(5787): 627-8.
24. Schatz DG. Antigen receptor genes and the evolution of a recombinase. Semin Immunol 2004; 16(4): 245-56.
25. Namboodiri AM, Pandey JP. Differential inhibition of trastuzumab-and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. Clin Exp Immunol 2011; 166(3): 361-5.
26. Clark MR, Cooper AB, Wang LD, Aifantis I. The pre-B cell receptor in B cell development: recent advances, persistent questions and conserved mechanisms. Curr Top Microbiol Immunol 2005; 290: 87-103.
27. Lanzavecchia A. Antigen uptake and accumulation in antigenspecific B cells. Immunol Rev 1987; 99: 39-51.
28. DeFranco AL. B-cell activation 2000. Immunol Rev 2000; 176: 5-9.
29. Parker DC. T cell-dependent B cell activation. Annu Rev Immunol 1993; 11: 331-60.
30. Diaz M, Casali P. Somatic immunoglobulin hypermutation. Curr Opin Immunol 2002; 14(2): 235-40.
31. He B, Qiao X, Klasse PJ, et al. HIV-1 envelope triggers polyclonal Ig class switch recombination through a CD40-independent mechanism involving BAFF and C-type lectin receptors. J Immunol 2006; 176(7): 3931-41.
32. Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113(16): 3716-25.
33. Kracker S, Radbruch A. Immunoglobulin class switching: in vitro induction and analysis. Methods Mol Biol 2004; 271: 149-59.
34. Wang J, Balog CI, Stavenhagen K, et al. Fc-glycosylation of IgG1 is modulated by B-cell stimuli. Mol Cell Proteomics 2011; 10(5): M110. 004655.
35. Pantaleo GaW, B. Retroviral Immunology: Immune Response and Restoration. Totowa, New Jersey: Human Press Inc.; 2001.
36. Huber M, Trkola A. Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 2007; 262(1): 5-25.
37. De Milito A. B lymphocyte dysfunctions in HIV infection. Curr HIV Res 2004; 2(1): 11-21.
38. De Milito A, Nilsson A, Titanji K, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004; 103(6): 2180-6.
39. Titanji K, Chiodi F, Bellocco R, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005; 19(17): 1947-55.
40. Connick E, Marr DG, Zhang XQ, et al. HIV-specific cellular and humoral immune responses in primary HIV infection. AIDS Res Hum Retroviruses 1996; 12(12): 1129-40.
41. Reimer CB, Black CM, Holman RC, et al. Hypergammaglobulinemia associated with human immunodeficiency virus infection. Monogr Allergy 1988; 23: 83-96.
42. Chung A, Dugast A, Robinson H, et al. Vector induced skewing of antibody Fc-effector functions. Retrovirology 2012; 9(Suppl 2): P361.
43. Ackerman ME, Dugast AS, McAndrew EG, et al. Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcgammaR2a and FcgammaR2b. J Virol 2013; 87(10): 5468-76.
44. Brown EP, Licht AF, Dugast AS, et al. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J Immunol Methods 2012; 386(1-2): 117-23.
45. Ackerman ME, Crispin M, Yu X, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Iinvest 2013; 123(5): 2183-92.
46. Forthal DN, Landucci G, Ding H, et al. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS 2011; 25(17): 2099-104.
47. Yates NL, Lucas JT, Nolen TL, et al. Multiple HIV-1-specific IgG3 responses decline during acute HIV-1: implications for detection of incident HIV infection. AIDS 2011; 25(17): 2089-97.
48. Lazar GA, Dang W, Karki S, et al. Engineered antibody Fc variants with enhanced effector function. Proc Natl Acad Sci USA 2006; 103(11): 4005-10.
49. Shields RL, Namenuk AK, Hong K, et al. High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. J Biol Chem 2001; 276(9): 6591-604.
50. Hamilton SR, Bobrowicz P, Bobrowicz B, et al. Production of complex human glycoproteins in yeast. Science 2003; 301(5637): 1244-6.
51. Yamane-Ohnuki N, Kinoshita S, Inoue-Urakubo M, et al. Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity. Biotechnol Bioeng 2004; 87(5): 614-22.
52. Schuster M, Umana P, Ferrara C, et al. Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 2005; 65(17): 7934-41.
53. Okeley NM, Alley SC, Anderson ME, et al. Development of orally active inhibitors of protein and cellular fucosylation. Proc Natl Acad Sci USA 2013; 110(14): 5404-9.
54. Tai YT, Horton HM, Kong SY, et al. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1. 24 antibody against multiple myeloma via augmented effector function. Blood 2012; 119(9): 2074-82.
55. Zalevsky J, Chamberlain AK, Horton HM, et al. Enhanced antibody half-life improves in vivo activity. Nat Biotechnol 2010; 28(2): 157-9.
56. Zalevsky J, Leung IW, Karki S, et al. The impact of Fc engineering on an anti-CD19 antibody: increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009; 113(16): 3735-43.
57. Junttila TT, Parsons K, Olsson C, et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res 2010; 70(11): 4481-9.
58. Moldt B, Shibata-Koyama M, Rakasz EG, et al. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol 2012; 86(11): 6189-96.
59. Moldt B, Schultz N, Dunlop DC, et al. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J Virol 2011; 85(20): 10572-81.
60. Hirbod T, Kaul R, Reichard C, et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers. AIDS 2008; 22(6): 727-35.
61. Hirbod T, Broliden K, Kaul R. Genital immunoglobulin A and HIV-1 protection: virus neutralization versus specificity. AIDS 2008; 22(17): 2401-2.
62. Tudor D, Derrien M, Diomede L, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgGseronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009; 2(5): 412-26.
63. Jefferis R. Isotype and glycoform selection for antibody therapeutics. Arch Biochem Biophys 2012; 526(2): 159-66.
64. Pandey JP. Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes. MAbs 2012; 4(5): 553-4.
65. Fudenberg HH, Fudenberg BR. Antibody to Hereditary Human Gamma-Globulin (Gm) Factor Resulting from Maternal-Fetal Incompatibility. Science 1964; 145(3628): 170-1.
66. Nimmerjahn F, Ravetch JV. Fc-receptors as regulators of immunity. Adv Immunol 2007; 96: 179-204.
67. Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24(1): 19-28.
68. Siberil S, Dutertre CA, Fridman WH, Teillaud JL. FcgammaR: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol 2007; 62(1): 26-33.
69. Kuo TT, Baker K, Yoshida M, et al. Neonatal Fc receptor: from immunity to therapeutics. J Clin Immunol 2010; 30(6): 777-89.
70. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8(1): 34-47.
71. Galon J, Gauchat JF, Mazieres N, et al. Soluble Fcgamma receptor type III (FcgammaRIII, CD16) triggers cell activation through interaction with complement receptors. J Immunol 1996; 157(3): 1184-92.
72. Chuang FY, Sassaroli M, Unkeless JC. Convergence of Fc gamma receptor IIA and Fc gamma receptor IIIB signaling pathways in human neutrophils. J Immunol 2000; 164(1): 350-60.
73. Fernandes MJ, Rollet-Labelle E, Pare G, et al. CD16b associates with high-density, detergent-resistant membranes in human neutrophils. Biochem J 2006; 393(Pt 1): 351-9.
74. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10(5): 328-43.
75. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21(21): 3940-7.
76. Regnault A, Lankar D, Lacabanne V, et al. Fcgamma receptormediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med 1999; 189(2): 371-80.
77. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest 2002; 110(1): 71-9.
78. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol 2007; 179(11): 7916-23.
79. Poonia B, Kijak GH, Pauza CD. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One 2010; 5(12): e15562.
80. Forthal DN, Gabriel EE, Wang A, Landucci G, Phan TB. Association of Fcgamma receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood 2012; 120(14): 2836-42.
81. Brouwer KC, Lal RB, Mirel LB, et al. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 2004; 18(8): 1187-94.
82. Deepe RN, Kistner-Griffin E, Martin JN, Deeks SG, Pandey JP. Epistatic interactions between Fc (GM) and FcgammaR genes and the host control of human immunodeficiency virus replication. Hum Immunol 2012; 73(3): 263-6.
83. Blank MC, Stefanescu RN, Masuda E, et al. Decreased transcription of the human FCGR2B gene mediated by the-343 G/C promoter polymorphism and association with systemic lupus erythematosus. Hum Genet 2005; 117(2-3): 220-7.
84. Ouma C, Davenport GC, Garcia S, et al. Functional haplotypes of Fc gamma (Fcgamma) receptor (FcgammaRIIA and FcgammaRIIIB) predict risk to repeated episodes of severe malarial anemia and mortality in Kenyan children. Hum Genet 2012; 131(2): 289-99.
85. Ravetch JV, Perussia B. Alternative membrane forms of Fc gamma RIII(CD16) on human natural killer cells and neutrophils. Cell type-specific expression of two genes that differ in single nucleotide substitutions. J Exp Med 1989; 170(2): 481-97.
86. Dugast AS, Tonelli A, Berger CT, et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 2011; 415(2): 160-7.
87. Arnold JN, Dwek RA, Rudd PM, Sim RB. Mannan binding lectin and its interaction with immunoglobulins in health and in disease. Immunol Lett 2006; 106(2): 103-10.
88. Anthony RM, Kobayashi T, Wermeling F, Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature 2011; 475(7354): 110-3.
89. Karsten CM, Pandey MK, Figge J, et al. Anti-inflammatory activity of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and dectin-1. Nat Med 2012; 18(9): 1401-6.
90. Shushakova N, Skokowa J, Schulman J, et al. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J Clin Invest 2002; 110(12): 1823-30.
91. Zhou MJ, Brown EJ. CR3 (Mac-1, alpha M beta 2, CD11b/CD18) and Fc gamma RIII cooperate in generation of a neutrophil respiratory burst: requirement for Fc gamma RIII and tyrosine phosphorylation. J Cell Biol 1994; 125(6): 1407-16.
92. Dong X, Storkus WJ, Salter RD. Binding and uptake of agalactosyl IgG by mannose receptor on macrophages and dendritic cells. J Immunol 1999; 163(10): 5427-34.
93. Mallery DL, McEwan WA, Bidgood SR, Towers GJ, Johnson CM, James LC. Antibodies mediate intracellular immunity through tripartite motif-containing 21 (TRIM21). Proc Nat Acad Sci USA 2010; 107(46): 19985-90.
94. Johansson ME, Thomsson KA, Hansson GC. Proteomic analyses of the two mucus layers of the colon barrier reveal that their main component, the Muc2 mucin, is strongly bound to the Fcgbp protein. J Proteome Res 2009; 8(7): 3549-57.
95. Wilson TJ, Fuchs A, Colonna M. Cutting edge: human FcRL4 and FcRL5 are receptors for IgA and IgG. J Immunol 2012; 188(10): 4741-5.
96. Santiago T, Kulemzin SV, Reshetnikova ES, et al. FCRLA is a resident endoplasmic reticulum protein that associates with intracellular Igs, IgM, IgG and IgA. Int Immunol 2011; 23(1): 43-53.
97. Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008; 8(1): 34-47.
98. Zhang Y, Hoppe AD, Swanson JA. Coordination of Fc receptor signaling regulates cellular commitment to phagocytosis. Proc Nat Acad Sci USA 2010; 107(45): 19332-7.
99. Caron E, Hall A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. Science 1998; 282(5394): 1717-21.
100. Vidarsson G, Stemerding AM, Stapleton NM, et al. FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. Blood 2006; 108(10): 3573-9.
101. Edberg JC, Kimberly RP. Modulation of Fc gamma and complement receptor function by the glycosylphosphatidylinositol-anchored form of Fc gamma RIII. J Immunol 1994; 152(12): 5826-35.
102. Wang SY, Veeramani S, Racila E, et al. Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009; 114(26): 5322-30.
103. Wang SY, Racila E, Taylor RP, Weiner GJ. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximabcoated target cells is inhibited by the C3b component of complement. Blood 2008; 111(3): 1456-63.
104. Lunnon K, Teeling JL, Tutt AL, Cragg MS, Glennie MJ, Perry VH. Systemic inflammation modulates Fc receptor expression on microglia during chronic neurodegeneration. J Immunol 2011; 186(12): 7215-24.
105. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006; 313(5787): 670-3.
106. Belostocki K, Park MS, Redecha PB, Masuda E, Salmon JE, Pricop L. FcgammaRIIa is a target for modulation by TNFalpha in human neutrophils. Clin Immunol 2005; 117(1): 78-86.
107. Appelberg R. Neutrophils and intracellular pathogens: beyond phagocytosis and killing. Trends Microbiol 2007; 15(2): 87-92.
108. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat Rev Immunol 2006; 6(3): 173-82.
109. Beauvillain C, Delneste Y, Scotet M, et al. Neutrophils efficiently cross-prime naive T cells in vivo. Blood 2007; 110(8): 2965-73.
110. Megiovanni AM, Sanchez F, Robledo-Sarmiento M, Morel C, Gluckman JC, Boudaly S. Polymorphonuclear neutrophils deliver activation signals and antigenic molecules to dendritic cells: a new link between leukocytes upstream of T lymphocytes. J Leukoc Biol 2006; 79(5): 977-88.
111. Pesce JT, Liu Z, Hamed H, et al. Neutrophils clear bacteria associated with parasitic nematodes augmenting the development of an effective Th2-type response. J Immunol 2008; 180(1): 464-74.
112. Tvinnereim AR, Hamilton SE, Harty JT. Neutrophil involvement in cross-priming CD8+ T cell responses to bacterial antigens. J Immunol 2004; 173(3): 1994-2002.
113. Kourtis AP, Hudgens MG, Kayira D. Neutrophil count in African mothers and newborns and HIV transmission risk. N Engl J Med 2012; 367(23): 2260-2.
114. Kinne TJ, Gupta S. Antibody-dependent cellular cytotoxicity by polymorphonuclear leucocytes in patients with AIDS and AIDSrelated complex. J Clin Lab Immunol 1989; 30(4): 153-6.
115. Saitoh T, Komano J, Saitoh Y, et al. Neutrophil extracellular traps mediate a host defense response to human immunodeficiency virus-1. Cell Host Microbe 2012; 12(1): 109-16.
116. Duval M, Posner MR, Cavacini LA. A bispecific antibody composed of a nonneutralizing antibody to the gp41 immunodominant region and an anti-CD89 antibody directs broad human immunodeficiency virus destruction by neutrophils. J Virol 2008; 82(9): 4671-4.
117. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22(11): 633-40.
118. Aasa-Chapman MM, Holuigue S, Aubin K, et al. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J Virol 2005; 79(5): 2823-30.
119. Ljunggren K, Moschese V, Broliden PA, et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990; 161(2): 198-202.
120. Ahmad A, Morisset R, Thomas R, Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr 1994; 7(5): 428-37.
121. Ojo-Amaize EA, Nishanian P, Keith DE Jr, et al. Antibodies to human immunodeficiency virus in human sera induce cellmediated lysis of human immunodeficiency virus-infected cells. J Immunol 1987; 139(7): 2458-63.
122. Deeks SG, Schweighardt B, Wrin T, et al. Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses. J Virol 2006; 80(12): 6155-64.
123. Brier AM, Chess L, Schlossman SF. Human antibody-dependent cellular cytotoxicity. Isolation and identification of a subpopulation of peripheral blood lymphocytes which kill antibody-coated autologous target cells. J Clin Invest 1975; 56(6): 1580-6.
124. Ahmad A, Menezes J. Antibody-dependent cellular cytotoxicity in HIV infections. Faseb J 1996; 10(2): 258-66.
125. Tyler DS, Stanley SD, Bartlett JA, Bolognesi DP, Weinhold KJ. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. J Surg Res 1998; 79(2): 115-20.
126. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174(4): 2185-9.
127. Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101(8): 3052-7.
128. Tagliabue A, Befus AD, Clark DA, Bienenstock J. Characteristics of natural killer cells in the murine intestinal epithelium and lamina propria. J Exp Med 1982; 155(6): 1785-96.
129. Eiras P, Leon F, Camarero C, et al. Intestinal intraepithelial lymphocytes contain a CD3-CD7+ subset expressing natural killer markers and a singular pattern of adhesion molecules. Scand J Immunol 2000; 52(1): 1-6.
130. Eiras P, Roldan E, Camarero C, Olivares F, Bootello A, Roy G. Flow cytometry description of a novel CD3-/CD7+ intraepithelial lymphocyte subset in human duodenal biopsies: potential diagnostic value in coeliac disease. Cytometry 1998; 34(2): 95-102.
131. Sips M, Sciaranghella G, Diefenbach T, et al. Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol 2012; 5(1): 30-40.
132. Holl V, Hemmerter S, Burrer R, et al. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J Immunol 2004; 173(10): 6274-83.
133. Tas M, Drexhage HA, Goudsmit J. A monocyte chemotaxis inhibiting factor in serum of HIV infected men shares epitopes with the HIV transmembrane protein gp41. Clin Exp Immunol 1988; 71(1): 13-8.
134. Wahl SM, Allen JB, Gartner S, et al. HIV-1 and its envelope glycoprotein down-regulate chemotactic ligand receptors and chemotactic function of peripheral blood monocytes. J Immunol 1989; 142(10): 3553-9.
135. Kedzierska K, Ellery P, Mak J, Lewin SR, Crowe SM, Jaworowski A. HIV-1 down-modulates gamma signaling chain of Fc gamma R in human macrophages: a possible mechanism for inhibition of phagocytosis. J Immunol 2002; 168(6): 2895-903.
136. Leeansyah E, Wines BD, Crowe SM, Jaworowski A. The mechanism underlying defective Fcgamma receptor-mediated phagocytosis by HIV-1-infected human monocyte-derived macrophages. J Immunol 2007; 178(2): 1096-104.
137. Webster NL, Kedzierska K, Azzam R, et al. Phagocytosis stimulates mobilization and shedding of intracellular CD16A in human monocytes and macrophages: inhibition by HIV-1 infection. J Leukoc Biol 2006; 79(2): 294-302.
138. Kedzierska K, Mak J, Mijch A, et al. Granulocyte-macrophage colony-stimulating factor augments phagocytosis of Mycobacterium avium complex by human immunodeficiency virus type 1-infected monocytes/macrophages in vitro and in vivo. J Infect Dis 2000; 181(1): 390-4.
139. Biggs BA, Hewish M, Kent S, Hayes K, Crowe SM. HIV-1 infection of human macrophages impairs phagocytosis and killing of Toxoplasma gondii. J Immunol 1995; 154(11): 6132-9.
140. Kedzierska K, Mak J, Jaworowski A, et al. nef-deleted HIV-1 inhibits phagocytosis by monocyte-derived macrophages in vitro but not by peripheral blood monocytes in vivo. AIDS 2001; 15(8): 945-55.
141. Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol 2003; 26(2): 247-63.
142. Crowe SM, Sonza S. HIV-1 can be recovered from a variety of cells including peripheral blood monocytes of patients receiving highly active antiretroviral therapy: a further obstacle to eradication. J Leukoc Biol 2000; 68(3): 345-50.
143. Crowe SM. Role of macrophages in the pathogenesis of human immunodeficiency virus (HIV) infection. Aust N Z J Med 1995; 25(6): 777-83.
144. Levy JA. Not an HIV cure, but encouraging new directions. N Engl J Med 2009; 360(7): 724-5.
145. Persaud D, Gay H, Ziemniak C, et al. Functional HIV Cure after Very Early ART of an Infected Infant. CROI 2013: 48LB.
146. Archin NM, Espeseth A, Parker D, Cheema M, Hazuda D, Margolis DM. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res Hum Retroviruses 2009; 25(2): 207-12.
147. Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature 2012; 487(7408): 482-5.
148. Contreras X, Schweneker M, Chen CS, et al. Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 2009; 284(11): 6782-9.
149. Matalon S, Palmer BE, Nold MF, et al. The histone deacetylase inhibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4(+) T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J Acquir Immune Defic Syndr 2010; 54(1): 1-9.
150. Reuse S, Calao M, Kabeya K, et al. Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection. PloS one 2009; 4(6): e6093.
151. Choi BS, Lee HS, Oh YT, et al. Novel histone deacetylase inhibitors CG05 and CG06 effectively reactivate latently infected HIV-1. AIDS 2010; 24(4): 609-11.
152. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 2004; 18(8): 1101-8.
153. Yin H, Zhang Y, Zhou X, Zhu H. Histonedeacetylase inhibitor Oxamflatin increase HIV-1 transcription by inducing histone modification in latently infected cells. Mol Biol Rep 2011; 38(8): 5071-8.
154. Zhu J, Gaiha GD, John SP, et al. Reactivation of latent HIV-1 by inhibition of BRD4. Cell reports 2012; 2(4): 807-16.
155. Cilo A, Sobolewski M, Bosch RJ, Coffin JM, Mellors J. Only a small fraction of HIV-1 proviruses in resting CD4+ T cells can be induced to produce virions ex vivo with anti-CD3/CD28 or Vorinostat. CROI 2013: 371.
156. Deeks SG. HIV: Shock and kill. Nature 2012; 487(7408): 439-40.
157. Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 2012; 36(3): 491-501.